Amlodipine

Amlodipine is a calcium channel blocker taken by mouth. The US label read, for Norvasc, lists hypertension, to lower blood pressure, and coronary artery disease: chronic stable angina, confirmed or suspected vasospastic angina, and, in patients with recently documented coronary artery disease by angiography and without heart failure or an ejection fraction under 40%, reducing the risk of hospitalization for angina and of a coronary revascularization procedure.

Also called Norvasc · Amlodipine besylate

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 17767; UNII 864V2Q084H. The label names the substance as amlodipine besylate, so UNII 864V2Q084H is the UNII of the salt form and is a broad match. MeSH descriptor D017311 is Amlodipine. Class: Calcium Channel Blocker (FDA established pharmacologic class, RxClass). The label read is the NORVASC (amlodipine besylate), Viatris Specialty LLC label, effective 2023-02-15 in openFDA (application NDA019787). Other amlodipine labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 40 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
40
Phase 3 or 4
30
Recruiting
5
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingNot yet recruitingCompletedTerminatedUnknown statusAll statuses
Phase 2006006
Phase 2/3101024
Phase 31171010
Phase 431111420
All phases52252640

Conditions these trials study

And 4 more.

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 25 more.

About this drug

Level
Substance
Mechanism
Not reported

Classification codes

  • UNII 864V2Q084H

Claims and evidence

Context People for whom the US label of amlodipine (Norvasc) lists an indication: hypertension, chronic stable angina, vasospastic angina, documented coronary artery disease

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The label does not state an age range in the passages read.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 4 inclusion criteria; exclusion criteria not stated
Included
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of NORVASC (amlodipine besylate), in the Viatris Specialty LLC version dated 2023-02-15 in openFDA, lists the medicine for the treatment of hypertension, to lower blood pressure; for the symptomatic treatment of chronic stable angina; for the treatment of confirmed or suspected vasospastic angina; and, in patients with recently documented coronary artery disease by angiography and without heart failure or an ejection fraction under 40%, to reduce the risk of hospitalization for angina and of a coronary revascularization procedure.

    Applies to Recipient not specified People for whom the US label of amlodipine (Norvasc) lists an indication: hypertension, chronic stable angina, vasospastic angina, documented coronary artery disease

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for NORVASC (amlodipine besylate tablets), Viatris Specialty LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 7367289c-b0b0-466a-83e2-558e2985c29f (manufacturer Viatris Specialty LLC, application NDA019787), returned on 2026-11-09. The label text is dated 2023-02-15 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0]
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2023-02-15
      Source state
      Current
      Version fingerprint
      bf6df4ca425b576e31632a7221984d7eb04668134e654d030073338ba914819d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for NORVASC (amlodipine besylate tablets), Viatris Specialty LLC label: indications and class description

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 7367289c-b0b0-466a-83e2-558e2985c29f (manufacturer Viatris Specialty LLC, application NDA019787), returned on 2026-11-09. The label text is dated 2023-02-15 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20230215.
      Retrieved
      Source effective date
      2023-02-15
      Source state
      Current
      Version fingerprint
      bf6df4ca425b576e31632a7221984d7eb04668134e654d030073338ba914819d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

AMLODIPINE BESYLATE

No label from the application holder was found in the openFDA label dataset for application NDA022026. This page does not show another labeler's label in its place.

AMTURNIDE

No label from the application holder was found in the openFDA label dataset for application NDA200045. This page does not show another labeler's label in its place.

AZOR

No label from the application holder was found in the openFDA label dataset for application NDA022100. This page does not show another labeler's label in its place.

CADUET

No label from the application holder was found in the openFDA label dataset for application NDA021540. This page does not show another labeler's label in its place.

CONSENSI

No label from the application holder was found in the openFDA label dataset for application NDA210045. This page does not show another labeler's label in its place.

EXFORGE

No label from the application holder was found in the openFDA label dataset for application NDA021990. This page does not show another labeler's label in its place.

EXFORGE HCT

No label from the application holder was found in the openFDA label dataset for application NDA022314. This page does not show another labeler's label in its place.

LOTREL

No label from the application holder was found in the openFDA label dataset for application NDA020364. This page does not show another labeler's label in its place.

NORLIQVA

No label from the application holder was found in the openFDA label dataset for application NDA214439. This page does not show another labeler's label in its place.

NORVASC

No label from the application holder was found in the openFDA label dataset for application NDA019787. This page does not show another labeler's label in its place.

PRESTALIA

No label from the application holder was found in the openFDA label dataset for application NDA205003. This page does not show another labeler's label in its place.

SDAMLO

No label from the application holder was found in the openFDA label dataset for application NDA219531. This page does not show another labeler's label in its place.

TEKAMLO

No label from the application holder was found in the openFDA label dataset for application NDA022545. This page does not show another labeler's label in its place.

TRIBENZOR

No label from the application holder was found in the openFDA label dataset for application NDA200175. This page does not show another labeler's label in its place.

TWYNSTA

No label from the application holder was found in the openFDA label dataset for application NDA022401. This page does not show another labeler's label in its place.

WIDAPLIK

No label from the application holder was found in the openFDA label dataset for application NDA219423. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA019787 NORVASC
  2. Approval NDA020364 LOTREL
  3. Supplemental approval NDA019787 NORVASC
  4. Supplemental approval NDA019787 NORVASC
  5. Supplemental approval NDA020364 LOTREL
  6. Supplemental approval NDA019787 NORVASC
  7. Approval NDA021540 CADUET
  8. Supplemental approval NDA019787 NORVASC
  9. Supplemental approval NDA020364 LOTREL
  10. Approval NDA021990 EXFORGE
  11. Approval NDA022100 AZOR
  12. Approval NDA022026 AMLODIPINE BESYLATE
  13. Supplemental approval NDA021990 EXFORGE
  14. Approval NDA022314 EXFORGE HCT
  15. Supplemental approval NDA022100 AZOR
  16. Approval NDA022401 TWYNSTA
  17. Approval NDA200175 TRIBENZOR
  18. Approval NDA022545 TEKAMLO
  19. Approval NDA200045 AMTURNIDE
  20. Approval NDA205003 PRESTALIA
  21. Approval NDA210045 CONSENSI
  22. Approval NDA214439 NORLIQVA
  23. Approval NDA219423 WIDAPLIK
  24. Approval NDA219531 SDAMLO

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 16

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 4 efficacy supplement approvals on record.

    ProductNDA019787

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.

    ProductNDA020364

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA021540

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA021990

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA022026

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA022100

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA022314

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA022401

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA022545

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA200045

Registry trials 40

Record details

Record id
cardio:amlodipine
Content hash
de40f4c9407e82a5bc37f4afb4a95cc1b17df047422e5203f2f4ff6f7f9653a8